The licensing agreement grants Nuance the exclusive rights to develop and commercialize AeroFact™, an innovate new therapy combining a well‐established pulmonary surfactant drug with proprietary vibrating mesh nebulizer aerosolization technology, in Greater China (Mainland China, Taiwan, Hong Kong and Macau).
The partners believe that AeroFact offers the prospect of an efficient, non‐invasive, and easy‐to‐use product with benefits over conventional invasively‐delivered lung surfactant that will improve clinical outcomes for the hundreds of thousands of premature babies around the world whose healthy development is threatened by RDS.